Immune response and laboratory markers in the spectrum of severity of COVID-19

Abstract

BACKGROUND: Serum antibodies to SARS-CoV-2, when measured early after disease onset, may add value to the diagnosis of COVID-19.

AIM: To examine the levels of serum antibodies to SARS-CoV-2 and laboratory blood parameters in hospitalized patients with COVID-19 of varying severity.

MATERIALS AND METHODS: In this retrospective cohort study, we examined laboratory markers of inflammation in patients with acute COVID-19 during the 1st week of hospitalization. The levels of serum antibodies to SARS-CoV-2 were studied using commercial test systems.

RESULTS: In 47% of hospitalized patients with COVID-19, during the first week of hospital stay, IgM and IgG antibodies to SARS-CoV-2 were detected, both in the case of a positive and negative PCR test. An average positive cor- relation of detected IgM and IgG with antibodies to the receptor-binding site of the S-protein of the SARS-CoV-2 virus is shown. In total, IgM and IgG antibodies to SARS-CoV-2 were most often detected in patients with a favorable course of the disease. Laboratory parameters in patients with moderate and severe COVID-19 were characterized by a significant increase in the level of serum C-reactive protein, an increase in the neutrophil-leukocyte ratio and fibrinogen level, in comparison with data from patients with a mild course of the disease. In mild cases of infection, a moderately negative correlation was revealed between the levels of antibodies to SARS-CoV-2 and NLR.

CONCLUSIONS: Detection of antibodies to SARS-CoV-2 in the early stages of hospitalization may be a predictor of a favorable outcome of the disease and serve as an additional criterion for the diagnosis of COVID-19 along with PCR analysis.

Keywords

SARS-CoV-2 / COVID-19 / antibodies / immunoglobulins / blood tests / disease severity

References

[1] Al-Tamimi M, Tarifi AA, Qaqish A, et al. Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals. Plos one. 2023;18(2):e0281689. DOI: 10.1371/journal.pone.0281689

[2] Al-Tamimi M., Tarifi A.A., Qaqish A. et al. Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals // Plos one. 2023. Vol. 18, No. 2. P. e0281689. DOI: 10.1371/journal.pone.0281689

[3] Kirkcaldy RD, King BA, Brooks JT. COVID-19 and postinfection immunity: limited evidence, many remaining questions. JAMA. 2020;323(22):2245–2246. DOI: 10.1001/jama.2020.7869

[4] Kirkcaldy R.D., King B.A., Brooks J.T. COVID-19 and postinfection immunity: limited evidence, many remaining questions // JAMA. 2020. Vol. 323, No. 22. P. 2245–2246. DOI: 10.1001/jama.2020.7869

[5] Rezaei M, Baghaei P, Sadr M, et al. Diagnosis of COVID-19 by serology in admitted patients with negative RT-PCR assay. Iran J Allergy Asthma Immunol. 2021;20(4):394–401.

[6] Rezaei M., Baghaei P., Sadr M. et al. Diagnosis of COVID-19 by serology in admitted patients with negative RT-PCR assay // Iran J. Allergy Asthma Immunol. 2021. Vol. 20, No. 4. P. 394–401.

[7] Shi J, Zheng J, Tai W, et al. A glycosylated RBD protein induces enhanced neutralizing antibodies against Omicron and other variants with improved protection against SARS-CoV-2 infection. J Virol. 2022;96(17):e0011822. DOI: 10.1128/jvi.00118-22

[8] Shi J., Zheng J., Tai W. et al. A glycosylated RBD protein induces enhanced neutralizing antibodies against Omicron and other variants with improved protection against SARS-CoV-2 infection // J. Virol. 2022. Vol. 96, No. 17. P. e0011822. DOI: 10.1128/jvi.00118-22

[9] Pink I, Raupach D, Fuge J, et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19. Infection. 2021;49(5):935–943. DOI: 10.1007/s15010-021-01615-8

[10] Pink I., Raupach D., Fuge J. et al. C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19 // Infection. 2021. Vol. 49, No. 5. P. 935–943. DOI: 10.1007/s15010-021-01615-8

[11] Vafadar Moradi E, Teimouri A, Rezaee R, et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality. Am J Emerg Med. 2021;40:11–14. DOI: 10.1016/j.ajem.2020.12.003

[12] Vafadar Moradi E., Teimouri A., Rezaee R. et al. Increased age, neutrophil-to-lymphocyte ratio (NLR) and white blood cells count are associated with higher COVID-19 mortality // Am. J. Emerg. Med. 2021. Vol. 40. P. 11–14. DOI: 10.1016/j.ajem.2020.12.003

[13] Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol. 2020;92(6):538–539. DOI: 10.1002/jmv.25721

[14] Wang Y., Kang H., Liu X., Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak // J. Med. Virol. 2020. Vol. 92, No. 6. P. 538–539. DOI: 10.1002/jmv.25721

[15] Plūme J, Galvanovskis A, Šmite S, et al. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients. J Transl Med. 2022;20(1):176. DOI: 10.1186/s12967-022-03382-y

[16] Plūme J., Galvanovskis A., Šmite S. et al. Early and strong antibody responses to SARS-CoV-2 predict disease severity in COVID-19 patients // J. Transl. Med. 2022. Vol. 20, No. 1. P. 176. DOI: 10.1186/s12967-022-03382-y

[17] Jurenka J, Nagyová A, Dababseh M, et al. Anti-SARS-CoV-2 antibody status at the time of hospital admission and the prognosis of patients with COVID-19: a prospective observational study. Infect Dis Rep. 2022;14(6):1004–1016. DOI: 10.3390/idr14060100

[18] Jurenka J., Nagyová A., Dababseh M. et al. Anti-SARS-CoV-2 antibody status at the time of hospital admission and the prognosis of patients with COVID-19: a prospective observational study // Infect. Dis. Rep. 2022. Vol. 14, No. 6. P. 1004–1016. DOI: 10.3390/idr14060100

[19] Kolb P, Giese S, Voll RE, et al. Immune complexes as culprits of immunopathology in severe COVID-19. Med Microbiol Immunol. 2023;212(2):185–191. DOI: 10.1007/s00430-022-00743-8

[20] Kolb P., Giese S., Voll R.E. et al. Immune complexes as culprits of immunopathology in severe COVID-19 // Med. Microbiol. Immunol. 2023. Vol. 212, No. 2. P. 185–191. DOI: 10.1007/s00430-022-00743-8

[21] Lucas C, Klein J, Sundaram ME, et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nat Med. 2021;27(7):1178–1186. DOI: 10.1038/s41591-021-01355-0

[22] Lucas C., Klein J., Sundaram M.E. et al. Delayed production of neutralizing antibodies correlates with fatal COVID-19 // Nat. Med. 2021. Vol. 27, No. 7. P. 1178–1186. DOI: 10.1038/s41591-021-01355-0

[23] Desheva Y, Lerner A, Shvedova T, et al. Pilot study results on antibodies to the S-and N-Proteins of SARS-CoV-2 in paired sera from COVID-19 patients with varying severity. Antibodies (Basel). 2023;12(1):19. DOI: 10.3390/antib12010019

[24] Desheva Y., Lerner A., Shvedova T. et al. Pilot study results on antibodies to the S-and N-Proteins of SARS-CoV-2 in paired sera from COVID-19 patients with varying severity // Antibodies (Basel). 2023. Vol. 12, No. 1. С. 19. DOI: 10.3390/antib12010019

[25] Stringer D, Braude P, Myint PK, et al. The role of C-reactive protein as a prognostic marker in COVID-19. Int J Epidemiol. 2021;50(2):420–429. DOI: 10.1093/ije/dyab012

[26] Stringer D., Braude P., Myint P.K. et al. The role of C-reactive protein as a prognostic marker in COVID-19 // Int. J. Epidemiol. 2021. Vol. 50, No. 2. P. 420–429. DOI: 10.1093/ije/dyab012

[27] Fazal M. C-reactive protein a promising biomarker of COVID-19 severity. Korean J Clin Lab Sci. 2021;53(3):201–207. DOI: 10.15324/kjcls.2021.53.3.201

[28] Fazal M. C-reactive protein a promising biomarker of COVID-19 severity // Korean J. Clin. Lab. Sci. 2021. Vol. 53, No. 3. P. 201–207. DOI: 10.15324/kjcls.2021.53.3.201

[29] Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6–e12. DOI: 10.1016/j.jinf.2020.04.002

[30] Liu Y., Du X., Chen J. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 // J. Infect. 2020. Vol. 81, No. 1. P. e6–e12. DOI: 10.1016/j.jinf.2020.04.002

RIGHTS & PERMISSIONS

Eco-Vector